Ranked #1 in 8 out of the 10 evaluated specialties by U.S. News
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
"Because almost all children with low-grade glioma survive, we need to consider their long term health, so we almost always use chemotherapy, even though it is much more difficult to administer than radiation. We don't always do what's easiest, we do what's right." - Mark Kieran, MD, PhD, Director, Pediatric Medical Neuro-Oncology
Glioma is a type of brain cancer, many of which are highly treatable and highly curable. The most common form of glioma is a low-grade astrocytoma, which has a cure rate of above 90 percent.
Glioma is a type of brain cancer originating from glial cells, which support the neurons in the brain, so they can communicate to one another, and allow a person to think. Glial cells are more likely to become cancer than neurons.
How Dana-Farber/Boston Children’s approaches glioma
The Low Grade Glioma Program at Boston Children’s is a multidisciplinary program dedicated to researching and delivering cutting edge treatments for low grade gliomas. Since many of our practicing physicians are also active researchers, your child will get the very best and up to date treatments available.
Patients with glioma are treated through the Glioma Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital.
The Low Grade Glioma Program is working on clinical trials for personalized medicine drugs, which is a new approach to medicine that targets specific parts of the cancer based on looking at the genes of a person. Each patient is unique, and we not only provide unique treatments, we provide unique care through programs, such as the Back to School Program.
Dana-Farber's Stop&Shop Pediatric Brain Tumor Survivors Program helps survivors of childhood cancer and their families address the long-term effects of therapy.
Glioma Overview: Reviewed by Mark Kieran, MD, PhD
© Boston Children’s Hospital, 2012
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”